Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002935 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
A Phase 2 study of Esophageal Cancer, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00002935: Completed Phase 2 study of Esophageal Cancer, sponsored by Roswell Park Cancer Institute.
NCT00002935 is a Phase 2 study of Esophageal Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 30 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002935, a Phase 2 study of Esophageal Cancer, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective treatment for esophageal cancer. PURPOSE: Phase II trial to study the effectiveness of photodynamic therapy in treating patients with Barrett's esophagus who have in situ esophageal cancer.
Conditions Studied
Interventions
- DRUG porfimer sodium
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1995-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00002935 record still lists
NCT00002935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which porfimer sodium is the first listed.
NCT00002935 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00002935 about?
NCT00002935 is a clinical study titled "Photodynamic Therapy in Treating Patients With Early Esophageal Cancer". RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective treatment for esophageal cancer. PURPOSE: Phase II trial to study the effectiveness of photodynamic therapy in treating patients with Barrett's esophagus...
What is the current status of trial NCT00002935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1995-10. Estimated completion is 2007-09.
What conditions does trial NCT00002935 study?
This clinical trial studies the following conditions: Esophageal Cancer.
What interventions are being tested in trial NCT00002935?
The interventions under investigation include: porfimer sodium (DRUG).
Who is sponsoring clinical trial NCT00002935?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002935 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002935's enrollment target sits among peer trials
30 98th of 123 higher than 24 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia